 Arcturus Therapeutics fell as much as 53 to 40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical companys COVID-19 vaccine updates. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. Barclays called the interim data of the vaccine candidate disappointing, according to a report cited by Seeking Alpha. Analyst Gena Wang wrote that higher dose animal studies showed some efficacy, but safety concerns limited further dose escalation. The firm downgraded its rating for Arcturus from overweight to equal weight. Barclays holds a price target of 46 for the stock. Raymond James also downgraded its rating from outperformto market perform, while Baird analysts downgraded the stock from outperform to neutral and lowered its price target from 79 to 69. 